<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023070</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-19-02132</org_study_id>
    <nct_id>NCT05023070</nct_id>
  </id_info>
  <brief_title>Investigation of the Pharmacokinetic Profile of Nanoemulsion CBD</brief_title>
  <official_title>Investigation of the Pharmacokinetic Profile of Nanoemulsion CBD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hurd,Yasmin, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hurd,Yasmin, Ph.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the current study is to evaluate the bioavaibiltiy of nanoemulsion CBD in normal&#xD;
      healthy Individuals. This is an open cross-over design study in healthy individuals to assess&#xD;
      the safety and pharmacokinetic (PK) effects of nanoemulsion cannabidiol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to determine the pharmacokinetics and pharmacodynamic profile of&#xD;
      CBD in normal healthy individuals under standard and high fat fed conditions.&#xD;
&#xD;
      CBD has recently gained significant attention as a potential treatment for various disorders.&#xD;
      One aspect for consideration in the development of CBD medication in capsule form is the poor&#xD;
      bioavailability of cannabinoids such as CBD to obtain clinically effective doses since only&#xD;
      ~4-6% of CBD is absorbed orally. This study will investigate the potential of CBD in a&#xD;
      nanoemulsion formulation in a capsule to enhance bioavailability, reduce the incidence of&#xD;
      gastrointestinal side effects, reduce first pass metabolism and enhance onset time. This PK&#xD;
      study will be conducted with standard meal and high fat conditions in normal healthy&#xD;
      volunteers in a cross-over design, separated by a washout period of 1 week. Healthy&#xD;
      volunteers are defined as having no significant health-related issues (i.e., the absence of&#xD;
      significant medical, psychosocial, or emotional conditions) that are verified by clinical and&#xD;
      psychiatric assessments.&#xD;
&#xD;
      The study will first evaluate in healthy volunteers the PK, tolerability and safety profiles&#xD;
      of a new CBD formulation designed to improve bioavailability.&#xD;
&#xD;
      Test conditions and order:&#xD;
&#xD;
        1. 200 mg CBD nanoemulsion (standard meal)&#xD;
&#xD;
        2. 400 mg CBD nanoemulsion (standard meal)&#xD;
&#xD;
        3. 400 mg Epidiolex (standard meal)&#xD;
&#xD;
        4. 400 mg CBD nanoemulsion (high fat meal)&#xD;
&#xD;
      Blood samples will be taken at -60,15, 30, 45 and 60 min and 1.5, 2, 3, 4, 6, 8, 10, 12 and&#xD;
      24 hours associated with administration of the CBD capsules.&#xD;
&#xD;
      Monitoring period for PK: 24 hours (plasma and urine PK). Participation in 4 test conditions&#xD;
      for a duration of approximately 4 weeks and a 1 week follow-up assessment. Total length of&#xD;
      in-house stay is 12 hours, with participants returning the following day for 24 hour time&#xD;
      point procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects of nanoemulsion cannabidiol.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and adverse effects</measure>
    <time_frame>Study Visit 1 Day</time_frame>
    <description>Safety and adverse effects will be assessed with the Systematic Assessment for Treatment Emergent Events (SAFTEE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Time point -60,15, 30, 45 and 60 minutes and 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours associated with administration of the CBD capsules.</time_frame>
    <description>Peak plasma concentration of CBD and its metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve (AUC)</measure>
    <time_frame>Time point -60,15, 30, 45 and 60 minutes and 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours associated with administration of the CBD capsules.</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak urine concentration of CBD (Umax)</measure>
    <time_frame>Time point -60 minutes and 2, 4, 6, 8, 10, 12, 24 hours associated with administration of the CBD capsules.</time_frame>
    <description>Peak urinary excretion of CBD and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the urine concentration curve (AUC)</measure>
    <time_frame>Time point -60 minutes and 2, 4, 6, 8, 10, 12, 24 hours associated with administration of the CBD capsules.</time_frame>
    <description>Area under the urine concentration versus time curve</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test condition 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nanoemulsion Cannabidiol 200 mg with standard meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test condition 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nanoemulsion Cannabidiol 400 mg with standard meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test condition 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidiolex 400 mg with standard meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test condition 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nanoemulsion Cannabidiol 400 mg with high fat meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Nanoemulsion Cannabidiol 200 mg</description>
    <arm_group_label>Test condition 1</arm_group_label>
    <other_name>ATL5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Nanoemulsion Cannabidiol 400 mg</description>
    <arm_group_label>Test condition 2</arm_group_label>
    <other_name>ATL5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Epidiolex 400 mg</description>
    <arm_group_label>Test condition 3</arm_group_label>
    <other_name>Epidiolex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Nanoemulsion Cannabidiol 400 mg</description>
    <arm_group_label>Test condition 4</arm_group_label>
    <other_name>ATL5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and give informed consent;&#xD;
&#xD;
          2. Individuals between 18 and 65 years old; Sex is used a biological factor (50% of&#xD;
             individuals recruited will be females, allowing sex comparisons).&#xD;
&#xD;
          3. English speakers.&#xD;
&#xD;
          4. Being healthy as determined by study physician according to screening medical and&#xD;
             psychiatric history, physical examination, vitals, ECG and safety laboratory values.&#xD;
             Only healthy volunteers with normal hepatic laboratory values will be enrolled.&#xD;
&#xD;
          5. Healthy volunteers who are medication- and drug-free, including free from nicotine and&#xD;
             any prescribed medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having present or past medical conditions, including a DSM-5 Axis I psychiatric&#xD;
             disorder, history of cardiac disease, arrhythmias, neurological disease of central&#xD;
             origin, head trauma, and seizures&#xD;
&#xD;
          2. Using any psychoactive drug (other than nicotine) in at least the past 7 days&#xD;
             (determined by lack of acute-opioid or other drugs related withdrawal symptoms and the&#xD;
             negative result of a urine drug screen including an opioid drug metabolite test, and&#xD;
             alcohol breathalyzer to detect alcohol intoxication);&#xD;
&#xD;
          3. Positive urine drug screen (cocaine, opiates, benzodiazepines, barbiturates,&#xD;
             amphetamines, morphine, methadone, methamphetamines, oxycodone, phencyclidine,&#xD;
             tricyclic antidepressant, tetrahydrocannabinol, buprenorphine,&#xD;
             methylenedioxymethamphetamine, propoxyphene);&#xD;
&#xD;
          4. Having a history of hypersensitivity to cannabinoids or any of the ingredients in the&#xD;
             product (gelatin and/or sesame oil);&#xD;
&#xD;
          5. Being pregnant or breastfeeding;&#xD;
&#xD;
          6. Not using an appropriate method of contraception such as hormonal contraception (oral&#xD;
             hormonal contraceptives, Depo-Provera, Nuva-Ring), intrauterine device (IUD),&#xD;
             sterilization, or double barrier method (combination of any two barrier methods used&#xD;
             simultaneously, i.e. condom, spermicide, diaphragm);&#xD;
&#xD;
          7. Participating in another pharmacotherapeutic trial in the past 3 months;&#xD;
&#xD;
          8. History of impaired renal function or elevated liver enzymes at prescreening. The&#xD;
             exclusionary lab values are: 3x nl AST/ALT, 1.5x bilirubin or 50% reduction in eGFR.&#xD;
&#xD;
          9. Participants who have used any medication, dietary supplements (and/or grape fruit&#xD;
             juice), or combination of medications and supplements known to alter the metabolism&#xD;
             of, or interact with CBD (bupropion, rifampin, barbiturates, phenothiazines,&#xD;
             cimetidine, etc.) 14 days prior to and during the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasmin Hurd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmin Hurd</last_name>
    <phone>(212) 585-4662</phone>
    <email>yasmin.hurd@mssm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Hurd, PhD</last_name>
      <phone>212-585-4662</phone>
      <email>yasmin.hurd@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Yasmin Hurd, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <keyword>Epidiolex</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

